Skip to content

XIENCE XPEDITION 1074275-33Recalls & reported problems

Abbott Vascular Inc. · XIENCE Xpedition LL Everolimus Eluting Coronary Stent System 2.75 mm x 33 mm / Rapid-Exchange · Class 3 · Implant

All models of XIENCE XPEDITION (41)

Data updated Oct 18, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
1
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 08717648162275), received between Mar 20, 2020 and Mar 20, 2020 — classified as 1 injury.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Most reported problems

Device problems

  • Adverse Event Without Identified Device or Use Problem1

Patient problems

  • Cardiac Arrest1
  • Embolism1
  • Myocardial Infarction1
  • Prolapse1
  • Thrombosis1
  • Ventricular Fibrillation1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • InjuryMar 20, 2020Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem

    SUBSEQUENT TO THE INITIAL 30 DAY MEDWATCH REPORT, THE FOLLOWING INFORMATION WAS RECEIVED: THE STENT THROMBOSIS, WITH ASSOCIATED ADVERSE EFFECTS OF MYOCARDIAL INFARCTION AND VENTRICULAR FIBRILLATION, RESOLVED ON (B)(6) 2020; HOWEVER, THE PATIENT WAS LEFT WITH COGNITIVE COMMUNICATION DIFFICULTIES, AS WELL AS PHYSICAL DECONDITIONING. NO ADDITIONAL INFORMATION WAS PROVIDED.

    Patient problems: Cardiac Arrest; Embolism; Myocardial Infarction; Prolapse; Thrombosis; Ventricular Fibrillation

    MAUDE report 9861612 ↗

Other Coronary drug-eluting stent devices

All Coronary drug-eluting stent devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page